THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS

THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS

A new generation of aromatase inhibitors and target therapy directed at cycline-dependent kinases 4 and 6 gives a new opportunity to treat metastatic breast cancer. However, the cost of innovative therapy remains high. We present results of the cost-consequence analysis of combination therapy with f...

Full description

Bibliographic Details
Main Authors: S. L. Pavlinsky, P. I. Shabalkin
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2017-09-01
Series:Сибирский онкологический журнал
Subjects:
qaly
cost-consequence analysis
inhibitor of cycline-dependent kinases 4/6
inhibitor of mammalian target of rapamycin
metastatic breast cancer
Online Access:https://www.siboncoj.ru/jour/article/view/565

Similar Items

Similar Items